Why Governments Still Ignore Ageing, and What Must Change with Dr Ilia Stambler

Why Governments Still Ignore Ageing, and What Must Change with Dr Ilia Stambler

What does it take to turn longevity science into real-world policy? In this episode, Daphna speaks with Dr Ilia Stambler, historian of longevity, published author, Chair of the International Longevity Alliance (ILA), and Chief Science Officer and Chairman of Vetek (Seniority) Association, about why advocacy and ecosystem-building may be just as important as the science itself.

Dr Stambler shares how the ILA has grown into a global network connecting 76 nonprofits across 66 countries, organising international conferences, and running the annual Longevity Day (1st October) and Longevity Month (October) campaigns. He points to concrete wins, including efforts to support the inclusion of ageing-related conditions in the ICD and the WHO's work programme.

The conversation gets honest about the real barriers to progress. Dr Stambler argues the problem isn't convincing governments that ageing matters, it's getting them to treat it with urgency. Despite ageing representing one of the largest disease burdens globally, it remains chronically underfunded and deprioritised, in part because the research timelines required don't fit neatly into political cycles.

He also reflects on the deeper intellectual questions underpinning the field: how to balance holism and reductionism, why historical perspective is essential for longevity researchers, and how the same patterns of enthusiasm, scepticism, and neglect have repeated across centuries of rejuvenation science.

Looking ahead to 2030, Dr Stambler highlights the need for better public education, evidence-based criteria for evaluating interventions, and growing grassroots motivation, because ultimately, he believes, a longer and healthier life begins with wanting one.


In This Episode:

  1. How the ILA operates across 66 countries and what it's achieved
  2. Why governments acknowledge ageing but still fail to act on it
  3. The long funding timelines longevity research demands — and why that's a political problem
  4. Which countries are currently leading on longevity policy
  5. Why solo science isn't enough and advocacy changes outcomes
  6. The "Death Valley of ideas" and how to get research across it
  7. Balancing holism and reductionism in longevity science
  8. Why the history of rejuvenation science keeps repeating itself
  9. What meaningful success in this field actually looks like.

Ilia Stambler, PhD

Chairman and CSO. Vetek (Seniority) Association – The Movement for Longevity and Quality of Life, Israel http://www.longevityisrael.org/

Chairman. International Longevity Alliance (ILA) http://www.longevityalliance.org/

Fellow. Department of Science, Technology and Society, Bar-Ilan University, Israel https://sts.biu.ac.il/

Author. A History of Life-Extensionism in the Twentieth Century; Longevity Promotion: Multidisciplinary Perspectives; Healthy Longevity: Policies and Practices http://longevityhistory.com

https://www.longevityhistory.com/about-the-author/

00:00 Welcome and Guest Intro

01:28 Staler Background and Mission

03:18 What the ILA Does

04:04 Key Wins and Campaigns

05:25 Public Misconceptions

07:27 Getting Governments to Act

09:14 Funding Research Long Term

10:49 Education and Conferences

12:05 Which Countries Lead

15:22 Why Advocacy Beats Solo Science

17:38 Advocacy Success Stories

20:48 Breaking Longevity Silos

21:23 Holism vs Reductionism

22:28 Why History Matters

24:17 Death Valley of Ideas

25:49 Rejuvenation Patterns Repeat

27:42 Misunderstood Longevity History

29:22 Balance and Modesty

31:23 Measuring Real Success

34:59 Making Longevity Policy

36:09 Rapid Fire Takeaways

38:58 Final Wrap Up

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(32)

Can One Drug Slow Ageing Across the Whole Body? LinkGevity’s Bid to Block Necrosis

Can One Drug Slow Ageing Across the Whole Body? LinkGevity’s Bid to Block Necrosis

What if heart disease, kidney disease and dementia share a common mechanism linked to ageing? And what if blocking a destructive form of cell death called necrosis could help protect several organs at...

16 Aug 1h 6min

How Much Control Do We Really Have Over Our Health? Spermidine, Autophagy and Patient Empowerment

How Much Control Do We Really Have Over Our Health? Spermidine, Autophagy and Patient Empowerment

At 39, Leslie Kenny was diagnosed with rheumatoid arthritis and lupus and says she was told she had around five years to live. More than two decades later, she is in long-term remission and has turned...

9 Aug 59min

The Hardest Problem in Longevity Is Human Behaviour with Dr Gil Blander, Founder of InsideTracker

The Hardest Problem in Longevity Is Human Behaviour with Dr Gil Blander, Founder of InsideTracker

Nearly two decades ago, Dr Gil Blander was trying to convince investors of an idea that, at the time, sounded radical: blood biomarkers should not only be used to diagnose disease, but to help healthy...

2 Aug 48min

Longevity Medicine Beyond ‘Failure-Based’ Healthcare with Dr Peter Scriven

Longevity Medicine Beyond ‘Failure-Based’ Healthcare with Dr Peter Scriven

In this episode of Beyond Longevity, Daphna speaks with Dr Peter Scriven, Co-Founder and Clinical & Scientific Director of LONGEVITY, about what longevity medicine should actually look like: moving fr...

26 Jul 1h 2min

Longevity at HLTH Why Healthy Ageing Is Finally Going Mainstream

Longevity at HLTH Why Healthy Ageing Is Finally Going Mainstream

In this episode of Beyond Longevity, Daphna speaks with Jody Tropeano Greene, Head of Content at HLTH, and Alexa Mikhail, Senior Content Lead at HLTH US, about how HLTH identifies the healthcare topic...

19 Jul 52min

From Blockbuster Medicine to Extending Healthspan with Sundeep Dugar PhD

From Blockbuster Medicine to Extending Healthspan with Sundeep Dugar PhD

On Beyond Longevity, host Daphna speaks with Dr Sundeep Dugar, PhD, co-founder of BlueOakNx and the scientists behind the blockbuster cholesterol medicines Zetia (ezetimibe) and Vytorin. He explains h...

12 Jul 59min

Robert Gielow on Longevity Products, Pharmacy Access and Consumer Trust with a focus on the German speaking market

Robert Gielow on Longevity Products, Pharmacy Access and Consumer Trust with a focus on the German speaking market

Daphna sat down with Robert Gielow, founder of Mentry Pharma, to discuss what it really takes for foreign supplement and longevity companies to enter the pharmacy markets of Germany, Austria and Switz...

5 Jul 1h

AI, Ageing And The Question Of Trust with Dr Filippo Dall'Armellina

AI, Ageing And The Question Of Trust with Dr Filippo Dall'Armellina

Biology is undergoing one of the biggest transformations in its history. AI is helping researchers analyse enormous datasets, predict protein structures, identify drug targets, and accelerate scientif...

28 Jun 57min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
romkapsel
rss-nysgjerrige-norge
liberal-halvtime
rekommandert
jss
villmarksliv
dekodet-2
abels-tarn
sinnsyn
vett-og-vitenskap-med-gaute-einevoll
fjellsportpodden
rss-overskuddsliv
rss-rekommandert
rss-paradigmepodden
tomprat-med-gunnar-tjomlid
diagnose
rss-inn-til-kjernen-med-sunniva-rose
nordnorsk-historie